Although　overall　survival　data　are　still　premature,　the　PROpel　study　found　radiological　progression-free　survival　(PFS)　benefits　of　abiraterone　and　olaparib　in　patients　with　metastatic　castration-resistant　prostate　cancer　(mCRPC).　However,　for　patients　who　have　not　been　genetically　tested　or　lack　BRCA1/2　mutations　(BRCAm),　this　combination　therapy　has　been　questioned　as　a　first-line　conventional　treatment　for　mCRPC,　mainly　due　to　significant　health　economics　and　side　effects.　In　our　retrospective　study,　we　found　that　treatment　with　low-dose　abiraterone　plus　olaparib　as　a　late-line　treatment　for　mCRPC　could　lead　to　prostate-specific　antigen　(PSA)　and　symptom　PFS　in　selective　cases　even　without　BRCAm.　The　median　PSA-PFS　was　8　months　(IQR:　6.5-11.5),　with　a　median　follow-up　duration　of　39.0　months　(IQR:　27.5-64.5).　Gene　tests　were　conducted　in　all　patients,　identifying　non-BRCA　mutations　through　ctDNA　testing　(24%),　tumor　tissue　testing　(12%),　or　both　(64%).　Adverse　events　occurred　in　72%　of　patients,　with　16%　experiencing　Grade　＞=　3　events.　Common　adverse　events　included　anemia　(64%),　decreased　appetite　(48%),　and　fatigue　(25%).　Our　findings　support　low-dose　abiraterone　plus　olaparib　as　a　potential　option　for　mCRPC　patients　without　BRCAm,　offering　manageable　safety　and　efficacy　profiles.